|本期目录/Table of Contents|

[1]孙芬芬 王 芳 殷国青 韩 睿 封明霞.7例经贝伐珠单抗治疗晚期肺腺癌致恶性心包积液临床有效性、安全性分析[J].中华肺部疾病杂志,2020,(04):451-455.[doi:10.3877/cma.j.issn.1674-6902.2020.04.004]
　Sun Fenfen,Wang Fang,Yin Guoqing,et al.Safety and efficacy of intravenous injection of bevacizumab for treatment of malignant pericardial effusion in advanced lung cancer patients[J].,2020,(04):451-455.[doi:10.3877/cma.j.issn.1674-6902.2020.04.004]
点击复制

7例经贝伐珠单抗治疗晚期肺腺癌致恶性心包积液临床有效性、安全性分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年04期
页码:
451-455
栏目:
论著
出版日期:
2020-08-20

文章信息/Info

Title:
Safety and efficacy of intravenous injection of bevacizumab for treatment of malignant pericardial effusion in advanced lung cancer patients
作者:
孙芬芬 王 芳 殷国青 韩 睿 封明霞
400012 重庆,陆军特色研究中心(大坪医院)呼吸与危重症医学科
Author(s):
Sun Fenfen;  Wang Fang;  Yin Guoqing;  Han Rui;  Feng Mingxia.
Department of Respiratory and Critical Care Medicine, Army Medical Center, Army Medical University, Chongqing 400012, China
Corresponding author
关键词:
贝伐珠单抗;  肺腺癌; 晚期;  恶性心包积液;  治疗;  有效性
Keywords:
Bevacizumab;  Advanced lung adenocarcinoma;  Malignant pericardial effusion;  Treatment;  Effectiveness
分类号:
R734.2,R563
DOI:
10.3877/cma.j.issn.1674-6902.2020.04.004
摘要:
目的 探讨贝伐珠单抗(bevacizumab, BEV)治疗晚期肺腺癌致恶性心包积液的有效性和安全性。方法 选择2014年1月至2019年4月我院收治的7例晚期肺腺癌合并中、大量恶性心包积液患者。在常规系统抗肿瘤治疗及对症治疗基础上接受静脉滴注BEV(400 mg/次)治疗,直至病情进展。对患者进行随访直至死亡,记录其病情是否缓解、无进展生存期、总生存时间以及不良反应。结果 5例患者在死亡前心包积液未再增加,其中2例患者完全缓解,3例患者部分缓解。另外2例患者症状未缓解。患者疾病无进展生存期平均为214天,疾病总生存期平均为24.28月。7例患者出现中有1例出现血栓性疾病,但经抗凝治疗后缓解,其余6例患者出现轻微药物相关不良事件。7例患者均未出现高血压。结论 在系统性抗肿瘤基础上静脉滴注BEV可有效控制恶性心包积液的生成、进展和复发,不良反应小,安全性高,但该结果仍需大规模临床研究进一步的验证。
Abstract:
Objective To evaluate the safety and efficacy of intravenous injection of intrapericardial bevacizumab(BEV)for treating symptomatic malignant pericardiac effusion(MPCE)in seven advanced lung cancer patients, who had previously undergone multiple lines of systemic therapy. Methods Seven advanced lung cancer patients with medium or large amount of MPCE admitted to our hospital from January 2014 to April 2019 were enrolled for this study. All the patients received intravenous injection of bevacizumab(400 mg every day)for two or three weeks until the symptoms were improved. Systemic therapy for the primary lung cancer was continued for all the patients during the BEV treatment. The medical record, including disease progression, progression-free survival, overall survival and side effects, had been reported until the patient died. Results The MPCE in five patients increased no more after BEV treatment. Among the five patients, complete remission was found in the symptoms of two patients and partial remission was found in three patients. Two patients showed no response with regard to the MPCE after BEV treatment. The median overall survival time was 214 days, and the progression-free survival time was 24.28 months. One patient suffered from thrombosis, which was remissed after the patient received anticoagulant therapy. The toxicity associated with BEV treatment of six patients was mild and manageable. Conclusion BEV may be an effective and safe treatment for MPCE in the patients with advanced lung cancer, which needs further verifications in large-scale clinical studies.

参考文献/References:

1 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2 Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders[J]. Cancer Res, 1997, 57(20): 4593-4599.
3 Assoun S, Brosseau S, Steinmetz C, et al. Bevacizumab in advanced lung cancer: state of the art[J]. Future Oncol, 2017, 13(28): 2515-2535.
4 Hanafy AF, El-Egaky AM, Mortada SA, et al. Development of implants for sustained release of 5-fluorouracil using low molecular weight biodegradable polymers[J]. Drug Discov Ther, 2009, 3(6): 287-295.
5 McAllister HA Jr, Hall RJ, Cooley DA. Tumors of the heart and pericardium[J]. Curr Probl Cardiol, 1999, 24(2): 57-116.
6 Jiang L, Li P, Gong Z, et al. Effective treatment for malignant pleuraleffusion and ascites with combined therapy of bevacizumab and cisplatin[J]. Anticancer Res, 2016, 36(3): 1313-1318.
7 Burazor M, Imazio G, Markel Y. Adler malignant pericardial effusion [J]. Cardiology, 2013, 124(4): 224-232.
8 Maisch B, Ristic AD, Pankuweit S, et al. Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin[J]. Eur Heart J, 2002, 23(20): 1625-1631.
9 Oida T, Mimatsu K, Kano H, et al. Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade[J]. World J Gastroenterol, 2010, 16(6): 740-744.
10 Chen D, Zhang Y, Shi F, et al. Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients[J]. Oncotarget, 2016, 7(32): 52436-52441.
11 Tamiya M, Suzuki H, Shiroyama T, et al. Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer[J]. Invest New Drugs, 2018, 36(4): 696-701.
12 Tezuka T, Hamada C, Ishida H, et al. Phase Ⅱ clinical study of modified FOLFOX7(intermittent oxaliplatin administration)plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study[J]. Invest New Drugs, 2013, 31(5): 1321-1329.
13 Reck M, Popat S, Reinmuth N, et al. Metastatic non-small cell lung cancer(NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2014, 25(S3): iii27-iii39.
14 中华医学会呼吸病学分会肺癌学组. 晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识(2016年版). 中国结核和呼吸杂志, 2016, 39(11): 839-849.
15 Zhou CC, Wu YL, Chen GY, et al. BEYOND: A Randomized, double-blind, placebo-controlled, multicenter, phase Ⅲ study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2015, 33(19): 2197-2204.
16 Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346: 92-98.
17 Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
18 Michael B, Mansfield A, Peikert T, et al. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion[J]. Curr Oncol Rep, 2013, 15(3): 207-216.
19 Bates DO. Vascular endothelial growth factors and vascular permeability [J]. Cardiovasc Res, 2010, 87(2): 262-271.
20 Burazor I, Imazio M, Markel G, et al. Malignant pericardial effusion[J]. Cardiology, 2013, 124(4): 224-232.
21 Halfdanarson TR, Hogan WJ, Moynihan TJ. Oncologic emergencies: diagnosis and treatment[J]. Mayo Clin Proc, 2006, 81(6): 835-848.
22 Pawlak Cieslik A, Szturmowicz M, Fijakowska A, et al. Diagnosis of malignant pericarditis: a single centre experience[J]. Kardiol Pol, 2012, 70(11): 1147-1153.
23 Hosomi Y, Ohkuma Y, Shibuya M. [Treatment of malignant pericardial effusion][J]. Gan To Kagaku Ryoho, 2008, 35(6): 906-909.
24 Refaat MM, Katz WE. Neoplastic pericardial effusion[J]. Clin Cardiol, 2011, 34(10): 593-598.
25 Vaitkus PT, Herrmann HC, LeWinter MM. Treatment of malignant pericardial effusion[J]. JAMA, 1994, 272(1): 59-64.
26 Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: part Ⅱ: Noninfectious pericarditis, pericardial effusion and constrictive pericarditis[J]. J Cardiovasc Med(Hagerstown), 2010, 11(11): 785-794.

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金资助项目(81802293)
通信作者: 封明霞, Email: 1971017228@qq.com
更新日期/Last Update: 2020-08-20